SARS-CoV-2 (COVID-19) ORF7a Antibody

blue ice or RT

Predicted reactivity based on immunogen sequence: SARS-CoV ORF7a: (73%).

IHC: 1 μ g/mL

Antibody validated: Immunohistochemistry in human samples. SARS-CoV-2 (COVID-19) ORF7a antibody can detect 2 ng of free peptide at 1 μ g/mL in ELISA. All other applications and species not yet tested.

SARS-CoV-2 (COVID-19) ORF7a Antibody is affinity chromatography purified via peptide column.

IgG

SARS-CoV-2 (COVID-19) ORF7a antibody is supplied in PBS containing 0.02% sodium azide.

SARS-CoV-2 (COVID-19) ORF7a antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

P0DTC7.1

43740573

ORF7a

Severe acute respiratory syndrome coronavirus 2

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). SARS-CoV-2 virus proteins include structural proteins, non-structural proteins and accessory factors. The structure of SARS-CoV-2 consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. SARS-CoV-2 non-structural protein is ORF1ab that consists of 16 proteins (nsp1-nsp16), while accessory factors include ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF7a and ORF7a. ORF7a plays a role as antagonist of host tetherin (BST2), disrupting its antiviral effect. It acts by binding to BST2 thereby interfering with its glycosylation. It may suppress small interfering RNA (siRNA) and may bind to host ITGAL, thereby playing a role in attachment or modulation of leukocytes (3).

Hui et al. Int J Infect Dis. 2020; 91:264-266.

Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) ORF7a in COVID-19 Patient Lung
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) ORF7a antibody (9285, 1 μ g/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 ORF7a protein was observed in macrophages of COVID-19 patient lung, but not in non-COVID-19 patient lung.